Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial.

Abstract

OBJECTIVE:

To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD).

PATIENTS AND METHODS:

This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1).

RESULTS:

Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported.

CONCLUSIONS:

This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.

• Authors: Giovanni Ragozzino, Edi Mattera, Elisa Madrid, Patrizia Salomone, Carmela Fasano, Filomena Gioia, Giusy Acerra, Raffaele del Guercio, Pasquale Federico
• Journal: Drugs in R&D (Drugs R D) Vol. 5 Issue 4 Pg. 185-90 ( 2004) ISSN: 1174-5886 [Print] New Zealand
• PMID: 15230623 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Blood Glucose
• Vasodilator Agents
• propionylcarnitine
• Carnitine

Topics

• Blood Glucose (drug effects)
• Carnitine (administration & dosage, analogs & derivatives, therapeutic use)
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Female
• Humans
• Injections, Intravenous
• Male
• Middle Aged
• Peripheral Vascular Diseases (complications, drug therapy)
• Pilot Projects
• Treatment Outcome
• Vasodilator Agents (administration & dosage, therapeutic use)